Literature DB >> 30474778

Trends in use of bilateral prophylactic mastectomy vs high-risk surveillance in unaffected carriers of inherited breast cancer syndromes in the Inherited Cancer Registry (ICARE).

Danielle A Henry1, Marie C Lee2, Deanna Almanza2, Kamran A Ahmed2, Weihong Sun2, David C Boulware3, Christine Laronga2.   

Abstract

PURPOSE: Awareness of inherited breast cancer has increased bilateral prophylactic mastectomy (BPM) among unaffected genetic mutation carriers, yet many still choose surveillance. We aimed to identify differences among women electing BPM vs high-risk surveillance.
METHODS: Participants from an IRB-approved database recruited from 11/2000 to 01/2017 with a deleterious/pathogenic, variant suspected deleterious, or likely pathogenic mutation in ≥ 1 of 11 genes with increased risk for breast cancer (per 2017 NCCN guidelines) were identified. Participants with breast cancer and males were excluded. Sociodemographic and clinical data were collected. The BPM and high-risk surveillance groups were compared using Wilcoxon, Fisher's Exact, and Pearson's Chi-Square analyses.
RESULTS: A total of 304 unaffected genetic mutation carriers were identified; 22 men were excluded. 113/282 (40%) underwent BPM. There was no significant difference in age, race, marital status, high school graduates, family history of breast cancer, breast biopsies, chemoprevention use, or understanding implications of genetic mutation carriage. BPM participants were more likely to have a prior pregnancy (p = 0.0005), college education (p = 0.04), income > $50,000/year (p = 0.01), first-degree relative with breast cancer (p = 0.04), higher total number of relatives with breast cancer (p = 0.01), and rate of risk-reducing salpingo-oophorectomy (p = < 0.0001). The high-risk surveillance group was more likely to have a history of ovarian cancer (p = 0.009) and cancer worry (p = < 0.0001).
CONCLUSIONS: BPM is a common but not universal choice among unaffected genetic carriers of inherited breast cancer syndromes. Parity, education, income, ovarian cancer history, first-degree relatives with breast cancer, and cancer worry play significant roles in these decisions.

Entities:  

Keywords:  Bilateral mastectomy; Family history; Genetics; High-risk surveillance; Inherited cancer; Prophylactic mastectomy

Mesh:

Year:  2018        PMID: 30474778      PMCID: PMC7771240          DOI: 10.1007/s10549-018-5057-7

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  26 in total

1.  Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial.

Authors:  Christiane Kuhl; Stefanie Weigel; Simone Schrading; Birke Arand; Heribert Bieling; Roy König; Bernd Tombach; Claudia Leutner; Andrea Rieber-Brambs; Dennis Nordhoff; Walter Heindel; Maximilian Reiser; Hans H Schild
Journal:  J Clin Oncol       Date:  2010-02-22       Impact factor: 44.544

2.  Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing.

Authors:  A-B Skytte; A-M Gerdes; M K Andersen; L Sunde; K Brøndum-Nielsen; M Waldstrøm; S Kølvraa; D Crüger
Journal:  Clin Genet       Date:  2010-01-06       Impact factor: 4.438

Review 3.  Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.

Authors:  Benjamin Powers; Tuya Pal; Christine Laronga
Journal:  Surg Oncol Clin N Am       Date:  2018-01       Impact factor: 3.495

4.  Long-term follow-up of Jewish women with a BRCA1 and BRCA2 mutation who underwent population genetic screening.

Authors:  Kelly A Metcalfe; Nida Mian; Melissa Enmore; Aletta Poll; Marcia Llacuachaqui; Sonia Nanda; Ping Sun; Kevin S Hughes; Steven A Narod
Journal:  Breast Cancer Res Treat       Date:  2012-01-13       Impact factor: 4.872

5.  Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.

Authors:  Susan M Domchek; Tara M Friebel; Christian F Singer; D Gareth Evans; Henry T Lynch; Claudine Isaacs; Judy E Garber; Susan L Neuhausen; Ellen Matloff; Rosalind Eeles; Gabriella Pichert; Laura Van t'veer; Nadine Tung; Jeffrey N Weitzel; Fergus J Couch; Wendy S Rubinstein; Patricia A Ganz; Mary B Daly; Olufunmilayo I Olopade; Gail Tomlinson; Joellen Schildkraut; Joanne L Blum; Timothy R Rebbeck
Journal:  JAMA       Date:  2010-09-01       Impact factor: 56.272

6.  Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.

Authors:  Marc D Schwartz; Claudine Isaacs; Kristi D Graves; Elizabeth Poggi; Beth N Peshkin; Christy Gell; Clinton Finch; Scott Kelly; Kathryn L Taylor; Lauren Perley
Journal:  Cancer       Date:  2011-06-29       Impact factor: 6.860

Review 7.  Genetic testing for cancer risk.

Authors:  B Ponder
Journal:  Science       Date:  1997-11-07       Impact factor: 47.728

Review 8.  Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.

Authors:  K A Metcalfe; W D Foulkes; C Kim-Sing; P Ainsworth; B Rosen; S Armel; A Poll; A Eisen; D Gilchrist; A Chudley; P Ghadirian; C Maugard; E G Lemire; P Sun; S A Narod
Journal:  Clin Genet       Date:  2008-03-12       Impact factor: 4.438

9.  Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.

Authors:  Elizabeth Gilbert; Emily C Zabor; Michelle Stempel; Debra Mangino; Alexandra Heerdt; Melissa Pilewskie
Journal:  Ann Surg Oncol       Date:  2017-08-01       Impact factor: 5.344

10.  Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.

Authors:  B A M Heemskerk-Gerritsen; M B E Menke-Pluijmers; A Jager; M M A Tilanus-Linthorst; L B Koppert; I M A Obdeijn; C H M van Deurzen; J M Collée; C Seynaeve; M J Hooning
Journal:  Ann Oncol       Date:  2013-04-10       Impact factor: 32.976

View more
  8 in total

Review 1.  Systemic Barriers to Risk-Reducing Interventions for Hereditary Cancer Syndromes: Implications for Health Care Inequities.

Authors:  Kathleen F Mittendorf; Sarah Knerr; Tia L Kauffman; Nangel M Lindberg; Katherine P Anderson; Heather Spencer Feigelson; Marian J Gilmore; Jessica Ezzell Hunter; Galen Joseph; Stephanie A Kraft; Jamilyn M Zepp; Sapna Syngal; Benjamin S Wilfond; Katrina A B Goddard
Journal:  JCO Precis Oncol       Date:  2021-11-03

2.  Time trends in uptake rates of risk-reducing mastectomy in Israeli asymptomatic BRCA1 and BRCA2 mutation carriers.

Authors:  Lee Galmor; Rinat Bernstein-Molho; Miri Sklair-Levy; Dana Madoursky-Feldman; Dov Zippel; Yael Laitman; Eitan Friedman
Journal:  Breast Cancer Res Treat       Date:  2020-09-30       Impact factor: 4.872

3.  Risk-reducing mastectomy: a case series of 124 procedures in Brazilian patients.

Authors:  Antônio Luiz Frasson; Martina Lichtenfels; Alessandra Anton Borba de Souza; Betina Vollbrecht; Ana Beatriz Falcone; Mônica Adriana Rodriguez Martinez Frasson; Fernanda Barbosa
Journal:  Breast Cancer Res Treat       Date:  2020-03-25       Impact factor: 4.872

4.  "High-Risk Breast Cancer Screening in BRCA1/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis".

Authors:  Shay Shraga; Albert Grinshpun; Aviad Zick; Luna Kadouri; Yogev Cohen; Ofra Maimon; Yael Adler-Levy; Galina Zeltzer; Avital Granit; Bella Maly; Einat Carmon; Vardiella Meiner; Tamar Sella; Tamar Hamburger; Tamar Peretz
Journal:  Front Oncol       Date:  2021-09-02       Impact factor: 6.244

Review 5.  Body Image in BRCA-Positive Young Women Following Bilateral Risk-Reducing Mastectomy: A Review of the Literature.

Authors:  Christa Torrisi
Journal:  Front Psychol       Date:  2021-12-16

6.  Contraception and Hormone Replacement Therapy in Healthy Carriers of Germline BRCA1/2 Genes Pathogenic Variants: Results from an Italian Survey.

Authors:  Claudia Massarotti; Barbara Buonomo; Miriam Dellino; Maria Campanella; Cristofaro De Stefano; Alberta Ferrari; Paola Anserini; Matteo Lambertini; Fedro A Peccatori
Journal:  Cancers (Basel)       Date:  2022-07-15       Impact factor: 6.575

7.  Risk-reducing mastectomy decisions among women with mutations in high- and moderate- penetrance breast cancer susceptibility genes.

Authors:  Jacob G Comeaux; Julie O Culver; John E Lee; Danielle Dondanville; Heather L McArthur; Emily Quinn; Nicholas Gorman; Charité Ricker; Ming Li; Caryn Lerman
Journal:  Mol Genet Genomic Med       Date:  2022-08-25       Impact factor: 2.473

8.  Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an ethical analysis.

Authors:  Erik Gustavsson; Giovanni Galvis; Niklas Juth
Journal:  BMC Med Ethics       Date:  2020-10-21       Impact factor: 2.652

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.